GT Biopharma, Inc. (GTBP)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenues | - | - | ||
| Research and development | 363 | 1,099 | ||
| Selling, general and administrative (including 4,000 and 120,000 from stock compensation for the three months ended june 30, 2025 and 2024, respectively, and 7,000 and 222,000 for the six months ended june 30, 2025 and 2024, respectively) | 1,150 | 833 | ||
| Loss from operations | -1,513 | -1,932 | ||
| Other income | 156 | - | ||
| Unrealized gain on short-term investments | - | - | ||
| Interest income | 38 | 32 | ||
| Gain on settlement of vendor payable | - | 998 | ||
| Change in fair value of warrant liability | 114 | -126 | ||
| Total other income (expense), net | 80 | 1,156 | ||
| Net loss | -1,433 | -776 | ||
| Dividends on preferred stock | 85 | - | ||
| Net loss attributable to common stockholders | -1,518 | -776 | ||
| Net loss per share - basic | -0.55 | -0.33 | ||
| Net loss per share - diluted | -0.55 | -0.33 | ||
| Weighted average common shares outstanding - basic | 2,771,765 | 2,345,087 | ||
| Weighted average common shares outstanding - diluted | 2,771,765 | 2,345,087 | ||